Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy

Biochemical and Biophysical Research Communications

Volumn 450, Issue 4, 2014, Pages 1581-1586

  Tikoo, Kulbhushan ^a   Lodea, Saritha ^a   Karpe, Pinakin Arun ^a   Kumar, Sandeep ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

AMPK and SIRT1; Calorie restriction; Diabetic nephropathy; PDE4

Indexed keywords

AMPK AND SIRT1; CALORIE RESTRICTION; DIABETIC NEPHROPATHY; PDE4;

ADENYLATE KINASE; AMINOPYRIDINES; ANIMALS; BENZAMIDES; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CALORIC RESTRICTION; CREATININE; CYCLOPROPANES; DIABETIC NEPHROPATHIES; IN SITU NICK-END LABELING; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIRTUIN 1;

EID: 84906082309     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.07.039     Document Type: Article

References (42)

1. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
2. P. Balakumar, M.K. Arora, S.S. Ganti, J. Reddy, and M. Singh Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions Pharmacol. Res. 60 2009 24 32
3. G. Wolf New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology Eur. J. Clin. Invest. 34 2004 785 796
4. P.M. Hall Prevention of progression in diabetic nephropathy Diabetes Spectr. 19 2006 18 24
5. D. Luis-Rodríguez, A. Martínez-Castelao, J.L. Górriz, F. De-Álvaro, and J.F. Navarro-González Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy World J. Diabetes 3 2012 7
6. S. Vollert, N. Kaessner, A. Heuser, G. Hanauer, A. Dieckmann, D. Knaack, H.P. Kley, R. Beume, and C. Weiss-Haljiti The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice Diabetologia 55 2012 2779 2788
7. S.K. Field Roflumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations Clin. Med. Insights Circ. Respir. Pulm. Med. 5 2011 57 70
8. E. Wouters, P. Teichmann, M. Brose, L. Fabbri, and K. Rabe, Effect of roflumilast on glucose levels in patients with COPD and diabetes mellitus type 2, in: European Respiratory Society Annual Congress, Barcelona, Spain, 2010, pp. 18-22.
9. E.F.M. Wouters, D. Bredenbroker, P. Teichmann, M. Brose, K.F. Rabe, L.M. Fabbri, and B. Goke Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 97 2012 E1720 E1725
10. P. Teichmann, M. Brose, B. Goke, K.F. Rabe, L.M. Fabbri, and E.F.M. Wouters Effects of roflumilast, a phosphodiesterase 4 inhibitor, on glucose homeostasis in patients with treatment-naive diabetes Am. J. Respir. Crit. Care Med. 181 2010 A4471
11. L. Fontana, L. Partridge, and V.D. Longo Extending healthy life span from yeast to humans Science 328 2010 321 326
12. K. Tikoo, D.N. Tripathi, D.G. Kabra, V. Sharma, and A.B. Gaikwad Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53 FEBS Lett. 581 2007 1071 1078
13. J.S. Stern, M.D. Gades, C.M. Wheeldon, and A.T. Borchers Calorie restriction in obesity: prevention of kidney disease in rodents J. Nutr. 131 2001 913S 917S
14. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway, Diabetes 60 (2011) 634-643.
15. M. Kitada, S. Kume, A. Takeda-Watanabe, K. Kanasaki, and D. Koya Sirtuins and renal diseases: relationship with aging and diabetic nephropathy Clin. Sci. 124 2013 153 164
16. D. Koya, K. Hayashi, M. Kitada, A. Kashiwagi, R. Kikkawa, and M. Haneda Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats J. Am. Soc. Nephrol. 14 2003 S250 S253
17. P.K. Datta, J.E. Moulder, B.L. Fish, E.P. Cohen, and E.A. Lianos, Induction of heme oxygenase 1 in radiation nephropathy: role of angiotensin II, Radiat. Res. (2009).
18. J. Kang, M.G. Jeong, S. Oh, E.J. Jang, H.K. Kim, and E.S. Hwang A FoxO1-dependent, but NRF2-independent induction of heme oxygenase-1 during muscle atrophy FEBS Lett. 588 2014 79 85
19. D.H. Lau, D.P. Mikhailidis, and C.S. Thompson The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study In Vivo 21 2007 851 854
20. B. RodreGuez-Iturbe, A. Ferrebuz, V. Vanegas, Y. Quiroz, F. Espinoza, H. Pons, and N.D. Vaziri Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage Kidney Int. 68 2005 2131 2142
21. V.M. Surse, J. Gupta, and K. Tikoo Esculetin induced changes in Mmp13 and Bmp6 gene expression and histone H3 modifications attenuate development of glomerulosclerosis in diabetic rats J. Mol. Endocrinol. 46 2011 245 254
22. D.S. Bendale, P.A. Karpe, R. Chhabra, S.P. Shete, H. Shah, and K. Tikoo 17 beta-Oestradiol prevents cardiovascular dysfunction in post-menopausal metabolic syndrome by affecting SIRT1/AMPK/H3 acetylation Br. J. Pharmacol. 170 2013 779 795
23. P.A. Karpe, and K. Tikoo Heat shock prevents insulin resistance induced vascular complications by augmenting angiotensin-(1-7) signalling Diabetes 63 2013 1124 1139
24. S.R. Mulay, A.B. Gaikwad, and K. Tikoo Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy Chem. Biol. Interact. 185 2010 137 142
25. E.O.N. Ptilovanciv, G.S. Fernandes, L.C. Teixeira, L.A. Reis, E.A. Pessoa, M.B. Convento, M.J. Simaes, G.A. Albertoni, N. Schor, and F.T. Borges Heme oxygenase 1 improves glucoses metabolism and kidney histological alterations in diabetic rats Diabetol. Metab. Syndr. 5 2013 3
26. G. Testa, F. Biasi, G. Poli, and E. Chiarpotto Calorie restriction and dietary restriction mimetics: a strategy for improving healthy aging and longevity Curr. Pharm. Des. 20 2014 2950 2977
27. M. Kitada, S. Kume, A. Takeda-Watanabe, S.-I. Tsuda, K. Kanasaki, and D. Koya Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-Aging effects, possibly including AMPK and SIRT1 activation Biochim. Biophys. Acta 2013 1830 4820 4827
28. J.H. Chung Metabolic benefits of inhibiting cAMP-PDEs with resveratrol Adipocyte 1 2012 256 258
29. J.H. Chung Using PDE inhibitors to harness the benefits of calorie restriction: lessons from resveratrol Aging (Albany NY) 4 2012 144
30. S.-J. Park, F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, and A.L. Brown Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases Cell 148 2012 421 433
31. M. Kitada, S. Kume, N. Imaizumi, and D. Koya Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway Diabetes 60 2011 634 643
32. W. He, Y. Wang, M.-Z. Zhang, L. You, L.S. Davis, H. Fan, H.-C. Yang, A.B. Fogo, R. Zent, and R.C. Harris Sirt1 activation protects the mouse renal medulla from oxidative injury J. Clin. Invest. 120 2010 1056
33. K. Hasegawa, S. Wakino, K. Yoshioka, S. Tatematsu, Y. Hara, H. Minakuchi, K. Sueyasu, N. Washida, H. Tokuyama, and M. Tzukerman Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function J. Biol. Chem. 285 2010 13045 13056
34. S. Kume, M. Haneda, K. Kanasaki, T. Sugimoto, S.-I. Araki, M. Isono, K. Isshiki, T. Uzu, A. Kashiwagi, and D. Koya Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation Free Radic. Biol. Med. 40 2006 2175 2182
35. T. Takahashi, H. Shimizu, H. Morimatsu, K. Maeshima, K. Inoue, R. Akagi, M. Matsumi, H. Katayama, and K. Morita Heme oxygenase-1 is an essential cytoprotective component in oxidative tissue injury induced by hemorrhagic shock J. Clin. Biochem. Nutr. 44 2009 28 40
36. N.G. Abraham, and A. Kappas Pharmacological and clinical aspects of heme oxygenase Pharmacol. Rev. 60 2008 79 127
37. M.L. Ferrandiz, and I. Devesa Inducers of heme oxygenase-1 Curr. Pharm. Des. 14 2008 473 486
38. L.W. Oberley Free radicals and diabetes Free Radic. Biol. Med. 5 1988 113 124
39. G.P. Sykiotis, I.G. Habeos, A.V. Samuelson, and D. Bohmann The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation Curr. Opin. Clin. Nutr. Metab. Care 14 2011 41
40. T. Jiang, Z. Huang, Y. Lin, Z. Zhang, D. Fang, and D.D. Zhang The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy Diabetes 59 2010 850 860
41. Y. Tan, T. Ichikawa, J. Li, Q. Si, H. Yang, X. Chen, C.S. Goldblatt, C.J. Meyer, X. Li, and L. Cai Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo Diabetes 60 2011 625 633
42. H. Ji, L. Wu, X. Ma, X. Ma, and G. Qin The effect of resveratrol on the expression of AdipoR1 in kidneys of diabetic nephropathy Mol. Biol. Rep. 41 4 2014 2151 2159